View By: Year Company Therapeutic Areas Drug Names
FDA-Approved Drugs
The following database contains a listing of drugs approved by the Food and Drug Administration (FDA) for sale in the United States. Drug information typically includes the drug name, approval status, indication of use, and clinical trial results.
Find out more about the types of drugs included in this listing.
Year: [2009] | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995
Cardiology/Vascular Diseases
Adcirca (tadalafil); Eli Lilly; For the treatment of pulmonary arterial hypertension, Approved May 2009
Atryn (antithrombin recombinant lyophilized powder for reconstitution); GTC BioTherapeutics; For the prevention of peri-operative and peri-partum thromboembolic events, Approved January 2009
Efient (prasugrel); Eli Lilly; for the prevention of thrombotic cardiovascular complications in acute coronary syndromes, Approved July 2009
Livalo (pitavastatin); Kowa Company; For the treatment of primary hyperlipidemia and mixed dyslipidemia, Approved August 2009
Multaq (dronedarone); Sanofi-aventis; For the treatment of paroxysmal or persistent atrial fibrillation or atrial flutter, Approved July 2009
Tyvaso (treprostinil); United Therapeutics; For the treatment of pulmonary arterial hypertension, Approved July 2009
Dermatology/Plastic Surgery
Stelara (ustekinumab); Centocor Ortho Biotech; For the treatment of plaque psoriasis, Approved September 2009
Vibativ (telavancin); Theravance; For the treatment of complicated skin and skin structure infections, Approved September 2009
Endocrinology
Cycloset, bromocriptine mesylate; VeroScience; For the treatment of type 2 diabetes mellitus, Approved May 2009
Onglyza (saxagliptin); Bristol-Myers Squibb; For the treatment of type 2 diabetes mellitus, Approved July 2009
Gastroenterology
Metozolv ODT (metoclopramide hydrochloride); Salix Pharmaceuticals; For the treatment of gastroesophageal reflux and diabetic gastroparesis, Approved September of 2009
Zenpep (pancrelipase); Eurand; For the treatment of pancreatic insufficiency due to cystic fibrosis or other conditions, Approved August 2009
Hematology
Elitek (rasburicase); sanofi-aventis; For the management of plasma uric acid levels in adults with malignancies, Approved October 2009
Feraheme (ferumoxytol); AMAG; For the treatment of iron deficiency anemia associated with chronic kidney disease, Approved June 2009
Folotyn (pralatrexate injection); Allos Therapeutics; For the treatment of peripheral T-cell lymphoma, Approved September 2009
Samsca (tolvaptan); Otsuka; For the treatment of hyponatremia, Approved May of 2009
Immunology/Infectious Diseases
Bepreve (bepotastine besilate ophthalmic solution); Ista Pharmaceuticals; For the treatment of itching associated with allergic conjunctivitis, Approved September 2009
Berinert (C1 Esterase Inhibitor (Human)); CSL Behring; For the treatment of abdominal or facial attacks of hereditary angioedema, Approved October 2009
Besivance (besifloxacin ophthalmic suspension); Bausch & Lomb; For the treatment of bacterial conjunctivitis, Approved June 2009
Cervarix [Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant; GlaxoSmithKline; For the prevention of cervical cancer and cervical intraepithelial neoplasia caused by HPV types 16 and 18, Approved October 2009
Coartem (artemether/lumefantrine); Novartis; For the treatment of malaria infections due to Plasmodium falciparum, Approved April 2009
Hiberix (Haemophilus b Conjugate Vaccine; Tetanus Toxoid Conjugate); GlaxoSmithKline; For the prevention of invasive disease caused by Haemophilus influenzae type b., August of 2009
Ilaris (canakinumab); Novartis; For the treatment of Cryopyrin-Associated Periodic Syndromes, Approved June 2009
Ixiaro (Japanese Encephalitis Vaccine, Inactivated, Adsorbed); Intercell AG; For the prevention of disease caused by Japanese encephalitis virus, Approved March 2009
Zirgan (ganciclovir ophthalmic gel); Sirion Therapeutics; For the treatment of acute herpetic keratitis, Approved September 2009
Musculoskeletal
Cimzia (certolizumab pegol); UCB; For the treatment of rheumatoid arthritis, Approved May of 2009
Colcrys (colchicine); Mutual Pharmaceuticals; For gout flares and familial Mediterranean fever, Approved October 2009
Extavia (Interferon beta-l b); Novartis; For the treatment of relapsing multiple sclerosis, Approved August of 2009
Sabril (vigabatrin); Lundbeck, Inc.; For the treatment of infantile spasms and complex partial seizures, Approved August 2009
Savella (milnacipran hydrochloride); Forest Laboratories; For the treatment of fibromyalgia, Approved January 2009
Simponi (golimumab); Centocor Ortho Biotech; For the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, Approved April 2009
Nephrology/Urology
Afinitor (everolimus); Novartis; For the treatment of renal cell carcinoma, Approved March 2009
Avastin (bevacizumab); Genentech; For the treatment of renal cell carcinoma, Approved July 2009
Gelnique (oxybutynin chloride); Watson Pharmaceuticals; For the treatment of overactive bladder, Approved January 2009
Votrient (pazopanib); GlaxoSmithKline; For the treatment of renal cell carcinoma, Approved October of 2009
Neurology
Axona (caprylidene); Accera; For the treatment of Alzheimer's disease, Approved March 2009
Cambia (diclofenac potassium for oral solution); Kowa Pharmaceuticals; For the treatment of migraine attacks, Approved June of 2009
Edluar (zolpidem tartrate); Orexo; For the treatment of insomnia, Approved March 2009
Embeda (morphine sulfate and naltrexone hydrochloride); King Pharmaceuticals; For the treatment of moderate to severe pain, Approved August of 2009
Intuniv (guanfacine extended-release); Shire; For the treatment of ADHD in children and adolescents, Approved September 2009
Onsolis (fentanyl buccal); BioDelivery Sciences; For the management of breakthrough cancer pain, Approved July 2009
Zipsor (diclofenac potassium); Xanodyne; For the treatment of mild to moderate acute pain, Approved June 2009
Obstetrics/Gynecology
Oncology
Ophthalmology
Acuvail (ketorolac tromethamine); Allergan; For the treatment of pain and inflammation following cataract surgery., Approved July 2009
Ozurdex (dexamethasone); Allergan; For the treatment of macular edema following branch retinal vein occlusion or central retinal vein occlusion, Approved June 2009
Pediatrics/Neonatology
Psychiatry/Psychology
Fanapt (iloperidone); Vanda; For the treatment of schizophrenia, Approved May of 2009
Saphris (asenapine); Schering-Plough; For the treatment of schizophrenia and manic or mixed bipolar 1 episodes, Approved August of 2009
Pulmonary/Respiratory Diseases
Rheumatology
Uloric (febuxostat); Takeda; For the treatment of chronic hyperuricemia in patients with gout, Approved February 2009
Trauma/Emergency Medicine
State of the Evidence: What is the Connection Between Chemicals and Breast Cancer? Action Card - 6 Actions to Reduce Your Exposure to Cancer-Causing Chemicals & Environmental Toxins Strong Voices Newsletter Key Facts About Breast Cancer Caminos Hacia La Prevención - Breast Cancer Prevention for Latinas
© The Breast Cancer Fund All Rights Reserved The Breast Cancer Fund2107 O'Farrell StreetSan Francisco, CA 94115
